Skip to Content
Find More Like This
Return to Search

Potent and selective mediators of cholesterol efflux

United States Patent

March 24, 2015
View the Complete Patent at the US Patent & Trademark Office
Lawrence Berkeley National Laboratory - Visit the Technology Transfer and Intellectual Property Management Department Website
The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABAC1 that parallels that of full-length apolipoproteins. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia and inflammation.
Bielicki; John K. (San Ramon, CA), Johansson; Jan (Danville, CA)
The Regents of the University of California (Oakland, CA)
12/ 519,116
December 13, 2007
STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT This invention was made with government support under Contract No. DE-AC02-05CH11231 awarded by the U.S. Department of Energy and Grant (Contract) No. R03-AG023153 awarded by the National Institutes of Aging. The Government has certain rights in this invention. The research leading to this invention was also funded by a sponsored research agreement with Artery Therapeutics, Inc. (LBNL Work for Other Agreement No. LB05-001119) and by Grant No. 13IT-0025 awarded by the Tobacco Related Disease Research Program of the State of California.